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Abstract
Tissue protein hypercatabolism (TPH) is a most important
feature in cancer cachexia, particularly with regard to the
skeletal muscle. The rat ascites hepatoma Yoshida AH-130
is a very suitable model system for studying the mechan-
isms involved in the processes that lead to tissue depletion,
since it induces in the host a rapid and progressive muscle
waste mainly due to TPH (Tessitore, L., G. Bonelli, and
F. M. Baccino. 1987. Biochem. J. 241:153-159). Detectable
plasma levels of tumor necrosis factor-a associated with
marked perturbations in the hormonal homeostasis have
been shown to concur in forcing metabolism into a catabolic
setting (Tessitore, L., P. Costelli, and F. M. Baccino. 1993.
Br. J. Cancer. 67:15-23). The present study was directed
to investigate if .2-adrenergic agonists, which are known to
favor skeletal muscle hypertrophy, could effectively antago-
nize the enhanced muscle protein breakdown in this cancer
cachexia model. One such agent, i.e., clenbuterol, indeed
largely prevented skeletal muscle waste in AH-130-bearing
rats by restoring protein degradative rates close to control
values. This normalization of protein breakdown rates was
achieved through a decrease of the hyperactivation of the
ATP-ubiquitin-dependent proteolytic pathway, as pre-
viously demonstrated in our laboratory (Llovera, M., C.
Garcfa-Martinez, N. Agell, M. Marzaibal, F. J. Lopez-Sori-
ano, and J. M. Argiles. 1994. FEBS (Fed. Eur. Biochem.
Soc.) Left. 338:311-318). By contrast, the drug did not exert
any measurable effect on various parenchymal organs, nor
did it modify the plasma level of corticosterone and insulin,
which were increased and decreased, respectively, in the
tumor hosts.
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The present data give new insights into the mechanisms
by which clenbuterol exerts its preventive effect on muscle
protein waste and seem to warrant the implementation of
experimental protocols involving the use of clenbuterol or
alike drugs in the treatment of pathological states involving
TPH, particularly in skeletal muscle and heart, such as in
the present model of cancer cachexia. (J. Clin. Invest. 1995.
95:2367-2372.) Key words: clenbuterol * tumor * protein
turnover * cachexia * ubiquitin
Introduction
Malignant neoplasms frequently induce a progressive loss of
lean body mass in the host associated with marked alterations in
the endocrine and metabolic homeostasis. The skeletal muscle,
which accounts for almost half of the whole body protein mass,
is severely affected in cancer cachexia ( 1-3 ) and evidence has
been provided for muscle protein waste as being associated with
enhanced turnover rates (4-9). Since cachexia tends to develop
at a rather advanced stage of the neoplastic growth, preventing
muscle waste in cancer patients is of a great potential clinical
interest. Whether the negative protein balance results from al-
tered rates of synthesis or breakdown or from changes on both
sides of muscle protein turnover is still debated, however (6,
10-12).
The rat ascites hepatoma Yoshida AH- 130 is a suitable
model system to study the mechanisms involved in the estab-
lishment of cachexia. Its growth causes in the host rapid and
progressive loss of body weight and tissue waste, particularly
in skeletal muscle. Acceleration of tissue protein breakdown
accounts for most of the waste in the AH-130 bearers (6, 13-
15). In particular, skeletal muscle hypercatabolism is mainly
due to hyperactivation of the ATP-ubiquitin-dependent proteo-
lytic system (16). Detectable plasma levels of tumor necrosis
factor-a (TNF) and perturbations in the hormonal homeostasis
(17) likely play an important role in forcing the metabolic
balance towards the catabolic side.
/32-adrenergic agonists are potent muscle growth promoters
in many animal species ( 18), resulting in skeletal muscle hyper-
trophy, while they cause a reduction of the body fat content
(19). These compositional alterations are associated with a re-
distribution of energy substrates, which are mobilized from stor-
age sites for utilization by tissues such as muscle and brown
adipose tissue (19). The intimate mechanisms by which these
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compounds exert such effects at the cellular level are still uncer-
tain (19), although changes in protein turnover are clearly in-
volved. Little is known, however, as to whether /2-agonists act
by potentiating the anabolic processes or depressing the cata-
bolic ones.
Aim of the present investigation has been to study the effects
of a 132-adrenergic agonist (clenbuterol), well known for its
selective anabolic action on the skeletal muscle, on tissue pro-
tein turnover in rats bearing a cachexia-generating fast-growing
tumor.
Methods
Animals, tumor inoculation, and treatment. Male Wistar rats (In-
terfauna, Barcelona, Spain) weighing - 100 g were used. The animals
were maintained on a regular light-dark cycle (light on from 08:00
a.m. to 08:00 p.m.) and had free access to food and water. The diet
(Panlab, Barcelona, Spain) consisted of54% carbohydrate, 17% protein,
and 5% fat (the residue was nondigestible material); the food intake
was measured daily. Rats were divided into two groups, namely controls
and tumor hosts. The latter received an intraperitoneal inoculum of
108 AH-130 Yoshida ascites hepatoma cells obtained from exponential
tumors (for details see reference 6). Both groups were further divided
into treated and untreated, the former being administered a daily s.c.
dose of clenbuterol (1 mg/kg b.w., dissolved in physiological solution),
the latter a corresponding volume of solvent.
On days 0,4, and 8 after tumor transplantation animals were weighed
and anesthetized with diethyl ether. The tumor was harvested from the
peritoneal cavity, its volume and cellularity evaluated, and cells sepa-
rated from the ascitic fluid by centrifugation at 100 g for 10 min.
Blood was collected from the abdominal aorta into heparinized tubes
and centrifuged (3500 g, 10 min, 40C) to obtain plasma. Tissues were
rapidly excised, weighed, and frozen in liquid nitrogen (see reference
6; for the adipose tissues see reference 20).
Protein turnover. Protein turnover rates were determined by a
method that, as previously discussed (6, 15), is very suitable for the
liver (21), yet suffers from considerable label recycling in skeletal
muscle (22); however, it offers the best compromise to monitor simulta-
neously protein synthesis and degradation in the same animal (see refer-
ence 23). Briefly, apparent rates of synthesis and degradation for pro-
teins of the slow turnover pool were evaluated by measuring the decay
in specific and total protein radioactivity after labeling in vivo, 24 h
before tumor transplantation, with a single intraperitoneal dose of so-
dium ['4C]bicarbonate (250 MACi/kg b.w.). Fractional rates of protein
degradation (kd), synthesis (k,), and accumulation (ka) were calculated
as follows:
kd = In (total protein radioactivity)/t
= ln (specific protein radioactivity)/t
ka = ln (total protein)/t
and expressed as percent per day.
Tissue protein was determined by the method of Lowry et al. (24),
using bovine serum albumin as working standard.
RNA isolation and Northern blot analysis. Total RNA from gastroc-
nemius muscle was extracted using the acid guanidinium isothiocyanate/
phenol/chloroform method as described by Chomczynski and Sacchi
(25). RNA samples (40 1g/ml) were denatured, subject to 1.2% agarose
gel electrophoresis and transferred to Hybond H membrane (Amersham
International, Buckinghamshire, UK). RNA was fixed to membrane by
illuminating with UV for 4 min.
Prehybridization was done in 50% formamide/5x SSC (0.3 M
NaCl, 65 mM sodium citrate)/5x Denhart's solution (lx Denhart's
solution is 0.1% polyvinylpyrolidone, 0.1% Ficoll, 0.1% BSA)/20 mM
sodium phosphate pH 6.8/0.1% SDS/100 ,ug/ml denatured salmon
sperm DNA overnight at 420C. Membranes were hybridized with appro-
priate probes ( I06- I0 cpm/ml) at 420C for 18 h. Nonspecifically bound
probe was removed by successive washes in 2x SSC (15 min at 550C,
twice), 2x SSC + 0.1% SDS (30 min at 550C) and 0.lx SSC + 0.1%
SDS (15 min at 550C, twice). Specific hybridization was then detected
by autoradiography (for more details see 16).
Radiolabeled probes were prepared by the random priming method
(Boehringer-Mannheim, Barcelona, Spain). The ubiquitin probe used
was a cDNA clone containing 12 bp of the second ubiquitin coding
sequence plus a complete third and fourth ubiquitin coding sequence
and 120 bp of the 3'-untranslated region of the chicken polyubiquitin
gene UB 1 (26). An actin probe was used as a control of loading. Filters
were exposed to X Omat AR-5 films (Eastman Kodak Co., Rochester,
NY) at -700C for 2-4 d.
Plasma hormones. Circulating corticosterone was evaluated by a rat
radioimmunoassay (IDS, Boldon, England). Insulin was measured by
radioimmunoassay by the method of Albano et al. (27), using rat insulin
as working standard.
Data presentation. Data are given as means-±-SD. Two-way factorial
analysis of variance was used to calculate the significance of differences.
As for fractional rates of protein turnover, significance of differences
was calculated by analysis of variance on linear regressions (28).
Chemicals. All enzymes and coenzymes were obtained from Boeh-
ringer-Mannheim or Sigma Chemical Co, (St. Louis, MO), sodium 14C-
bicarbonate (53 mCi/mmol) from New England Nuclear (Boston, MA).
Clenbuterol was kindly provided by Smithkline Beechman Pharmaceuti-
cals (Betchworth, Surrey, UK).
Results
The rat ascites hepatoma Yoshida AH-130 grew exponentially
for 4-5 d then shifted into a stationary phase approximately by
day 8 after transplantation, as previously shown (29). This
growth pattern was not significantly affected by clenbuterol
(Table I).
Clenbuterol did not alter the food intake either in controls
or in tumor bearers. The hypophagia occurring during tumor
growth (15, 17) persisted unchanged in treated animals: the
average daily food intake was 25 and 23 g on day 0, and 14,
and 15 g on day 8 after tumor inoculation, respectively, in
untreated and treated tumor hosts; in treated and untreated non-
tumor bearing animals it amounted to 24 and 23 g, respectively,
over the whole experimental period.
As shown in Table I, the loss of body weight in tumor
bearers became prominent by day 8 and was not affected by
clenbuterol. A marked reduction of white adipose tissue mass
was already detectable at day 4 in clenbuterol-treated controls;
this tissue was also diminished in day 8 tumor bearers, yet not
further affected to a significant degree by the drug treatment.
Both liver and brown adipose tissue were hypotrophic 4 d after
tumor inoculation and even more so by day 8; no significant
protective effect was exerted by clenbuterol on either tissue.
Quite different was the pattern with regard to skeletal and
heart muscles. An early and progressive decrease in wet weight
(data not shown) and protein content was elicited by tumor
growth (Table H), with gastrocnemius and heart being affected
earlier and more severely than soleus, as previously reported
(6). Treatment with clenbuterol substantially prevented the pro-
tein waste in each tissue, since day 4 for gastrocnemius and
heart, by day 8 for the soleus. This protective effect was also
noticeable in terms of wet tissue weight for the skeletal muscles,
but not for the heart (data not shown); a similar discrepancy
between heart wet weight and protein content had already been
observed in AH-130 tumor bearers treated with anti-TNF anti-
bodies (30). In agreement with previous observations, clenbu-
2368 Costelli et al.
Table I. Body and Tissue Weight and Tumor Growth in AH-130 Hosts after Clenbuterol Administration
Body weight (g) Total tumor
cell number Tumor
Time Tumor Treatment Initial Final Liver WAT IBAT (X 10-6) volume
mg mg mg ml
Day 4 No None 183±9 220±13 5725±164 397±41 163±21
Clenbuterol 189±6 217±8 5605±267 318±36 167±32
Yes None 181±9 206±25 5168±320* 370±47 110±15* 2976±220 19±2
Clenbuterol 185±8 205±13 5051±275* 359±56 110±24* 2631±799 17±3
Day 8 No None 185±12 253±17 6437±267 564±31 162±23
Clenbuterol 182±12 216±23 6378±718 459±22 135±20
Yes None 188±11 199±15t 4829±740t 421±23* 83±9t 8133±937 56±14
Clenbuterol 183±9 198±17* 4890±428t 381±68* 103±17* 7406±1206 51±15
Data are expressed as means±SD. Tissue weights are expressed as percentages of initial body weight. Significance of the differences (two-way
factorial analysis of variance): * P < 0.05; 1P < 0.01 (tumor burden) n = 4 and 6 for nontumor and tumor bearers, respectively.
terol afforded a significant trophic action (protein increase)
on muscles in nontumor bearers as well, particularly on the
gastrocnemius and less on the heart, while the soleus was not
significantly affected (Table H).
Protein turnover in gastrocnemius and heart was evaluated
to assess by which regulation, whether on synthesis or on degra-
dation or both, the protein-sparing action of clenbuterol was
exerted. As previously reported (6, 15), rates of protein degra-
dation were enhanced in both muscles examined in consequence
of tumor growth, while synthesis remained virtually unchanged,
resulting in protein accumulation rates lower than in controls
(Table HI). On treatment with clenbuterol, the elevation of
protein breakdown rates was suppressed and protein accumula-
tion rates returned similar to those in controls (Table HI). No
detectable effect was observed with regard to protein synthesis
rates. Likewise in nontumor bearers, the gastrocnemius and
heart hypertrophy observed on drug treatment appeared to result
from a marked decrease in protein catabolic rates, while synthe-
sis rates were not significantly affected (Table III).
As previously shown (16), the accelerated muscle protein
breakdown in the AH-130 hosts may be achieved through acti-
vation of the ATP-ubiquitin-dependent proteolytic system. As
Table II. Muscle Protein Content
Time Tumor Treatment Gastrocnemius Soleus Heart
Day 0 No None 45.8±3.5 2.29±0.11 45.5±3.4
Day 4 No None 70.6±1.4 2.70±0.08 62.2±2.3
No Clenbuterol 73.2±1.3 2.84±0.16 59.1±10.1
Yes None 60.4±3.9** 2.62±0.20 54.2±4.2*
Yes Clenbuterol 64.8±2.2* 2.89±0.26 67.3±9.1$
Day 8 No None 87.8±2.7 3.51±0.24 67.2±4.3
No Clenbuterol 99.1±3.6* 3.44±0.31 74.1±3.2*
Yes None 55.7±4.1** 2.70±0.26** 55.8±6.0*
Yes Clenbuterol 78.1±3.8tt 3.16±0.186* 87.6±9.4**$$
Data (means±SD) are expressed as mg of protein per whole organ. Statistical
comparison of the data (two-way factorial analysis of variance) showed significant
effects for both tumor burden and treatment. Interactions: * P < 0.05 and ** P
< 0.01 (tumor bearing vs. nontumor bearing); tP < 0.05 and $$ P < 0.01 (treat-
ment vs. placebo). n = 4 and 6 for nontumor and tumor bearers respectively.
shown in Fig. 1, two polyubiquitin mRNA species (2.4 and
1.2 kb) were found in gastrocnemius muscle. Tumor-bearing
animals showed an increased expression of the polyubiquitin
genes in relation with the corresponding control animals: over
severalfold (2.4 kb) and 14-fold (1.2 kb). When the tumor-
bearing animals received clenbuterol, this activation was sup-
pressed, the values obtained being over twice than those ob-
tained in the untreated controls for both ubiquitin mRNA
(Fig. 1).
Corticosterone was elevated and insulin decreased in the
blood plasma of AH-130 hosts, as previously observed (17).
When these animals were administered clenbuterol, neither in-
sulin nor corticosterone changes were affected, suggesting that
the drug effects were not mediated through these hormones. In
nontumor bearers the treatment did not modify corticosterone,
while insulin concentrations decreased below the control values
(Table IV).
Discussion
Muscle protein waste is a main feature in cancer cachexia and,
generally, is mostly ascribed to enhanced tissue protein catabo-
lism (4-9, 15). So far, most therapeutic approaches to cancer
cachexia have been designed on the assumption that tissue waste
merely results from undernutrition or tumor-host competition,
yet parenteral nutrition or overfeeding have proven to be only
marginally or, at best, temporarily effective (31-33). More-
over, in some cases the tumor itself apparently took advantage
of such regimen more than the patient (32, 34).
The rat tumor model used in the present study quickly causes
progressive body weight loss and tissue protein waste, the latter
associated with TPH (6, 15) likely mediated by production of
cytokines such as TNF and alterations in the hormonal homeo-
stasis (17). The beneficial effects of treatments with anti-TNF
antibodies (30) or with drugs interfering with the development
of TPH (35) have been previously reported. The present obser-
vations show that treatment of the AH-130 hosts with clenbu-
terol largely abolished the protein waste in the gastrocnemius
and heart by restoring normal rates of protein degradation. This
is in agreement with previous reports that 162-adrenergic agonists
may antagonize the skeletal muscle depletion in different situa-
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Table III. Muscle Protein Turnover
k. kd k.
Gastrocnemius
Controls
r
slope
Controls + clenbuterol
r
slope
F
AH-130
r
slope
F
AH-130 + clenbuterol
r
slope
F
Heart
Controls
r
slope
Controls + clenbuterol
r
slope
F
AH-130
r
slope
F
AH-130 + clenbuterol
r
slope
F
10.30
-0.992
- 1.92±0.29
10.28
-0.986
-1.95±0.25
5.51
9.06
-0.995
- 1.77±0.27
4.68
8.86
-0.978
-1.75±0.17
4.97
10.81
-0.991
-2.15±0.44
10.45
-0.994
-2.08±0.50
3.28
12.94
-0.988
-2.19±0.57
4.12
10.63
-0.992
-2.12±0.46
5.03
2.36
-0.989
-32± 1.16
1.05**
-0.995
- 15±2.41
396
7.02**
-0.991
-79±7.53
498
2.43f
-0.994
-33±1.49
500
6.54
-0.994
-481±24
3.25**
-0.998
-257±23
409
9.87**
-0.990
-639±99
48.24
6.96t
-0.987
-506±61
24.07
5.65
0.996
3.98±0.19
7.18**
0.990
5.38±0.86
21.32
-1.01**
-0.858
-0.63±0.26
248
4.21l
0.966
2.79±0.35
140
4.46
0.993
2.39±0.17
6.65**
0.996
4.00±0.15
512
1.81
-0.991
-0.89±0.21
197
8.20*1
0.990
5.32±0.22
1560
For further details see Methods section. Fractional rates of protein syn-
thesis (k,), degradation (kd) and accumulation (ka) are expressed as per-
cent per day (n = S for each time point) and were calculated over the
time interval 0-8 d, since linearity of radioactivity decay during the
experimental period (days 0-2-4-6-8) was tested. Variance between
groups is indicated by SE of the slope (t X SE of the slope, t being the
95% value of student's t test for n-2 (see Lee and Lee) (28). Significance
of the differences: ** P < 0.01 vs. controls; * P < 0.05 and 11 P
< 0.01 vs. AH-130.
tions. Thus clenbuterol markedly attenuates the muscle atrophy
by denervation (36, 37) or by hindlimb suspension (38). More-
over, this drug can increase the skeletal muscle mass in mice
with genetic muscle dystrophy (39). More recently, clenbuterol
has been reported to accelerate the recovery of the skeletal
muscle mass after challenge with bacterial lipopolysaccharides
or surgical stress (40, 41 ).
It is not clear how these agents modulate tissue protein
turnover, though some indirect evidence for an effect on protein
catabolism has been provided. Reeds et al. (42) did not observe
any change in the gastrocnemius protein synthesis rates after
dietary administration of clenbuterol to rats, and concluded that
decreased breakdown had to be involved. An indirect confirma-
tion that /2-agonists may act by reducing protein catabolism
came from a recent study in which the intracellular amino acid
content of rat gastrocnemius was shown to increase after treat-
ment with metaproterenol (43). In addition, glutamine, and
alanine were found to be released at reduced rates from isolated
muscles in the presence of the,3-adrenergic agonist isoprenaline
(44). The present study is totally consistent with these previous
reports. Both the prevention of muscle protein depletion in AH-
130 tumor bearers and the increase of muscle protein mass in
nontumor bearers afforded by clenbuterol appeared to result
from regulations on the catabolic side, respectively, by restoring
protein breakdown to normal rates or by reducing them to less
than normal levels. Moreover, in agreement with previous re-
ports (45, 46), the effects of the drug appeared more marked
on a fast-twitch (gastrocnemius) than on a slow-twitch muscle
(soleus). The trophic action of 62-adrenergic agonists is gener-
ally regarded as quite selective for the skeletal muscle (19,
38, 42). After treatment with such drugs, however, cardiac
hypertrophy has been reported in some studies (42,47), yet not
in others (38). In the present study, clenbuterol administration
exerted quite comparable effects on gastrocnemius and heart in
both control and tumor-bearing animals.
The precise mechanisms by which intracellular proteins are
degraded is largely unknown, although it is accepted that prote-
olysis may occur inside and outside the lysosomes. Lysosomic
proteases, in particular cathepsins, do not seem to be largely
involved in the degradation of myofibrillar proteins in rat skele-
tal muscle (35, 48). The ATP-ubiquitin-dependent proteolytic
system is postulated to account for the turnover of short-lived
proteins (49) or for abnormal proteins formed during stress
such as heat-shock (50). However, it has been suggested that
the activity of this system can also be related to the turnover
of long-lived proteins such as those found in skeletal muscle
(51). Recently, this proteolytic system has been involved in
the perturbations of protein metabolism consequent to fasting
and denervation atrophy (52). Previous studies from our labora-
tory have shown that the lysosomal pathway is only marginally
involved in the development of muscle protein hypercatabolism
in the AH-130 hosts (16, 35), while an important activation of
the ATP-dependent proteolysis seems to be the leading mecha-
nism (16). It is very interesting to observe that the preventive
effect exerted by clenbuterol on the acceleration of muscle pro-
tein breakdown is due to complete repression of the hyperex-
pression of the ubiquitin mRNAs. The association between the
increased ubiquitin gene expression and the proteolytic activity
in this tumor model has been recently studied by our laboratory
(53). Moreover, it is important to underline that in control rats
receiving clenbuterol, the ubiquitin mRNAs expression is below
the basal value. To the best of our knowledge, this is the first
report showing that the effect of clenbuterol on muscle protein
turnover is due to down-regulation of the ATP-ubiquitin-de-
pendent proteolytic system.
32-adrenergic agonists are also known to display their ana-
bolic effects in different situations of perturbed endocrine status
such as diabetes, adrenalectomy, or castration (47, 54), sug-
gesting that their action might involve hormonal modulations.
However, as far as insulin and corticosterone are concerned,
the present study suggests that this is not the case for the AH-
130 hosts, since the altered plasma level of neither hormone was
corrected by the treatment. However, the hormonal involvement
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cannot be ruled out since the ,82-agonist could have altered
hormone sensitivity (55).
Another important action of /32-adrenergic agonists is to
reduce the body fat content by directly stimulating lipolysis
(19); tissue-specific modulations in lipoprotein lipase activity
could constitute an additional mechanism for promoting a de-
creased lipid accretion in adipose tissue (56). In addition, these
drugs enhance the overall energy expenditure and increase the
thermogenesis, thereby dissipating the excess energy derived
from the lipids mobilized (19). The present cachexia model in
itself is characterized by extensive lipid mobilization (20, 57),
associated with decreased activity of tissue lipoprotein lipase
(20). The lack of effect of clenbuterol on adipose tissue in AH-
130 hosts thus probably reflects the fact that lipid mobilization
was already occurring in these animals and could not be easily
stimulated further. When the drug treatment was applied to
control rats, however, the adipose tissue mass decreased with
respect to untreated controls (by 20%), in agreement with previ-
ous reports (38, 58).
In conclusion, the present results indicate that clenbuterol
Table IV. Plasma Levels of Insulin and Corticosterone
Time Tumor Treatment Corticosterone Insulin
mg/dl MIU/mi
Days 4-8 No None 156±37 200±26
Day 4 No Clenbuterol 177±47 115±20
Yes None 463±156* 86±9*
Yes Clenbuterol 434±186* 70±10*
Day 8 No Clenbuterol 167±42 151±13
Yes None 463±145* 98±11*
Yes Clenbuterol 580±171* 79±10*
Data are means±SD. Significance of the differences (two-way factorial
analysis of variance): * P < 0.05 (tumor burden). n = 4 and 6 for
nontumor and tumor bearers, respectively.
Figure 1. Northern blots of gas-
trocnemius muscle extracts from
tumor-bearing rats. Expression of
a mRNA 2.4 kb ubiquitin mRNA in skeletal gas-
* mRNA 1.2 kb trocnemius muscles from control(C), control treated with clenbut-
erol (C+CL), 7-d tumor-bearing
(TB) and 7-d tumor-bearing
treated with clenbuterol
(TB+CL). It was detected after
hybridization with a cDNA probe
containing a region of the chicken
A/:* polyubiquitin gene UB1. Autora-
9* diographs were subjected to scan-
ning densitometry. Ethidium bro-
/* 9 mide (EtBr) was used for total
RNA quantitation. The results of
3 different animals are shown and
expressed as arbitrary units. Sig-
WAX** nificance of the differences (two-
way factorial analysis of vari-
ance): P < 0.01 (tumor burden);
C C+CL TB TB+CL P < 0.01 (treatment).
exerted a selective, powerful protective action on heart and
skeletal muscle by antagonizing the enhanced protein degrada-
tion and the resulting protein loss that characterize cachexia in
AH-130 tumor-bearing rats. These observations suggest that, in
spite of its numerous side effects, clenbuterol could reveal as a
convenient therapeutic tool in pathological states wherein mus-
cle protein hypercatabolism is a critical feature such as cancer
cachexia or other wasting diseases.
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